279 related articles for article (PubMed ID: 28728992)
1. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
[TBL] [Abstract][Full Text] [Related]
2. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
[TBL] [Abstract][Full Text] [Related]
4. Association between age and sex and mortality after adjuvant therapy for renal cancer.
Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Jilaveanu LB; Puligandla M; Weiss SA; Wang XV; Zito C; Flaherty KT; Boeke M; Neumeister V; Camp RL; Adeniran A; Pins M; Manola J; DiPaola RS; Haas NB; Kluger HM
Clin Cancer Res; 2018 Jan; 24(1):217-223. PubMed ID: 29066509
[No Abstract] [Full Text] [Related]
7. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
Narayan V; Puligandla M; Haas NB; Subramanian P; DiPaola RS; Uzzo R
J Urol; 2019 Jan; 201(1):62-68. PubMed ID: 30130544
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy after nephrectomy for renal cell carcinoma.
Ravaud A
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
[TBL] [Abstract][Full Text] [Related]
10. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy.
Schafhauser W; Ebert A; Brod J; Petsch S; Schrott KM
Anticancer Res; 1999; 19(2C):1573-8. PubMed ID: 10365148
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
[TBL] [Abstract][Full Text] [Related]
12. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience.
Bazzi WM; Sjoberg DD; Feuerstein MA; Maschino A; Verma S; Bernstein M; O'Brien MF; Jang T; Lowrance W; Motzer RJ; Russo P
J Urol; 2015 Jun; 193(6):1911-6. PubMed ID: 25524244
[TBL] [Abstract][Full Text] [Related]
14. The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma.
Capitanio U; Matloob R; Suardi N; Abdollah F; Castiglione F; Di Trapani D; Russo A; Briganti A; Carenzi C; Salonia A; Montorsi F; Rigatti P; Bertini R
Urologia; 2012; 79(2):109-15. PubMed ID: 22610843
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
Karam JA; Puligandla M; Flaherty KT; Uzzo RG; Matin SF; Pins MR; Wood CG; Kane C; Jewett MAS; Kim SE; Dutcher JP; DiPaola RS; Haas NB
BJU Int; 2022 Jun; 129(6):718-722. PubMed ID: 34480522
[TBL] [Abstract][Full Text] [Related]
16. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.
Chipollini J; Abel EJ; Peyton CC; Boulware DC; Karam JA; Margulis V; Master VA; Zargar-Shoshtari K; Matin SF; Sexton WJ; Raman JD; Wood CG; Spiess PE
Clin Genitourin Cancer; 2018 Apr; 16(2):e443-e450. PubMed ID: 29113770
[TBL] [Abstract][Full Text] [Related]
17. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Tollefson MK; Lohse CM; Costello BA; Cheville JC; Leibovich BC
Eur Urol; 2017 Apr; 71(4):560-567. PubMed ID: 27671144
[TBL] [Abstract][Full Text] [Related]
18. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
20. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Zhao F; Cella D; Manola J; DiPaola RS; Wagner LI; Haas NSB
Support Care Cancer; 2018 Jun; 26(6):1889-1895. PubMed ID: 29274030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
